A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

377

Enrollment

INDUSTRY

Sponsor class

Conditions

Gynecologic Cancers
Platinum-Sensitive Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer (PSOC)

Interventions

DRUG: IMGN151
DRUG: Carboplatin
DRUG: Bevacizumab
DRUG: Olaparib

Sponsor

AbbVie

Collaborators

[object Object]